$PFE News

Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer's Bear Case Is Breaking

Pfizer: Still Mispriced By Mr. Market (Earnings Preview)

Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo

Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far

Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?

PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use

Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump Takes Another Swing at Drug Industry in Made-in-USA Push

Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season